article thumbnail

After Roche breakup, Blueprint Medicines finds Gavreto a new home at Rigel

Fierce Pharma

As Roche officially abandoned cancer drug Gavreto, its former partner Blueprint Medicines has found the RET inhibitor a new owner in the U.S. | As Roche officially abandoned cancer drug Gavreto, its former partner Blueprint Medicines has found the RET inhibitor a new U.S. owner in Rigel Pharmaceuticals.

Medicine 287
article thumbnail

Europe names hundreds of critical medicines in quest to counter drug shortages

Fierce Pharma

Tuesday, the European Medicines Agency laid out a list of more than 300 critical generic drugs that could fall prey to future shortages. Over the past several years, drug shortages have vexed doctors and patients on both sides of the Atlantic, prompting lawmakers and government agencies to take action in both Europe and the U.S.

Medicine 360
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Top three trends in precision medicine

Pharmaceutical Technology

An innovative approach to healthcare, precision medicine is a new medical model that takes into account individual differences in genes, environments, and lifestyles to drive better outcomes through medicine.

Medicine 105
article thumbnail

ESC 2024: UK's George Medicines posts positive results for triple-combo blood pressure drug on heels of FDA submission

Fierce Pharma

ESC 2024: UK's George Medicines posts positive results for triple-combo blood pressure drug on heels of FDA submission fkansteiner Fri, 08/30/2024 - 15:54

Medicine 263
article thumbnail

Eli Lilly Plans $4.5B Medicine Foundry to Foster Innovations in Drug Manufacturing

MedCity News

Lilly Medicine Foundry will research new ways to manufacture medicines. Medicine Foundry to Foster Innovations in Drug Manufacturing appeared first on MedCity News. The post Eli Lilly Plans $4.5B

article thumbnail

Europe's CHMP endorses clutch of new medicines including Astellas, J&J and Ipsen offerings

Fierce Pharma

While it may well be the dog days of summer, European drug regulators are showing no signs of slowing down in their review of new medicines and proposed label expansions. While it may well be the dog days of summer, European drug regulators are showing no signs of slowing down in their review of new medicines and proposed label expansions.

Medicine 159
article thumbnail

AI in Precision Medicine: Transforming Obesity Treatment

Pharma IQ

Discover how artificial intelligence is revolutionizing the field of precision medicine. In this insightful article, Tim O’Connor, Chief Data Scientist at Phenomix Sciences, discusses the pivotal role.

Medicine 130